SCHEMBL6576609

SCHEMBL6576609

CC1(C)O[C@@H]2[C@H](O1)[C@@H](c1nc(C3CC3)no1)O[C@H]2n1cnc2c(Cl)ncnc21

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PI4KA P42356 1/20 0.43
PI4K2B Q8TCG2 1/20 0.43
PI4K2A Q9BTU6 1/20 0.43
PI4KB Q9UBF8 1/20 0.43
PDE4A P27815 1/20 0.41
PDE4B Q07343 1/20 0.41
PDE4C Q08493 1/20 0.41
PDE4D Q08499 1/20 0.41
AMD1 P17707 2/20 0.39
RXFP1 Q9HBX9 2/20 0.39
P2RX1 P51575 1/20 0.36
P2RX3 P56373 1/20 0.36
P2RX4 Q99571 1/20 0.36
STING1 Q86WV6 1/20 0.36
TYMP P19971 1/20 0.34
SLC29A1 Q99808 1/20 0.33
ADORA3 P0DMS8 2/20 0.32
ADORA2A P29274 2/20 0.32
ADORA2B P29275 2/20 0.32
ADORA1 P30542 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6573028 0.82 TYMP (0.48) PDE4APDE4BPDE4CPDE4DTYMP
SCHEMBL6575010 0.82 PI4KA (0.33) PI4KAPI4K2BPI4K2API4KBPDE4A
SCHEMBL7205095 0.79 ADORA1 (0.46) ADORA3ADORA2AADORA2BADORA1
SCHEMBL5529325 0.76 PI4KA (0.44) PI4KAPI4K2BPI4K2API4KBPDE4A
SCHEMBL6572952 0.76 PI4KA (0.46) PI4KAPI4K2BPI4K2API4KBPDE4A
SCHEMBL14390216 0.76 PI4KA (0.44) PI4KAPI4K2BPI4K2API4KBPDE4A
SCHEMBL7189813 0.76 PI4KA (0.44) PI4KAPI4K2BPI4K2API4KBPDE4A
SCHEMBL5529334 0.76 PI4KA (0.44) PI4KAPI4K2BPI4K2API4KBPDE4A
SCHEMBL6796631 0.76 PI4KA (0.46) PI4KAPI4K2BPI4K2API4KBPDE4A
SCHEMBL14264199 0.76 PI4KA (0.54) PI4KAPI4K2BPI4K2API4KBPDE4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1090019-B1 ADENOSINE DERIVATIVES GLAXO GROUP LTD (GB) 2004-09-29 EP disclosed
EP-1447407-A1 Adenosine derivatives GLAXO GROUP LIMITED (GB) 2004-08-18 EP disclosed
US-6677316-B2 TREATING ISCHEMIA, CARDIOVASCULAR DISORDERS, STROKE, PAIN, NERVOUS SYSTEM DISORDERS OR SLEEP APNEA; ADENOSINE A1 RECEPTOR AGONIST; 2-(3-(TERT-BUTYL)-1,2,4-OXADIAZOL-5-YL)-5-(6-(ISOBUTYLAMINO)-9H-PURIN-9-YL) TETRAHYDROFURAN-3,4-DIOL SMITHKLINE BEECHAM CORPORATION 2004-01-13 US disclosed
US-20030096788-A1 Adenosine derivatives GLAXO WELLCOME INC. 2003-05-22 US disclosed
US-6492348-B1 Adenosine derivatives SMITHKLINE BEECHAM CORPORATION 2002-12-10 US disclosed
EP-1090019-A1 ADENOSINE DERIVATIVES GLAXO GROUP LIMITED (GB) 2001-04-11 EP disclosed
WO-1999067262-A1 ADENOSINE DERIVATIVES GLAXO GROUP LIMITED (GB) 1999-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030096788-A1 Adenosine derivatives ADORA3, ADORA2A, ADORA1 PI4KA 1727/4885PI4K2B 2708/4885PI4K2A 1729/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.